Adial Pharmaceuticals secures FDA support for AD04 as Phase 3 clinical trials move forward
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in addiction treatment development, has received a pivotal endorsement from the U.S. Food and Drug Administration (FDA) ... Read More
Eli Lilly’s Emgality gets FDA green light for migraine prevention
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy ... Read More